IOVANCE BIOTHERAPEUTICS, INC. 8-K

What Happened

• On February 24, 2026, Iovance Biotherapeutics, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025 via a press release furnished as Exhibit 99.1 to an 8-K filing. The company also updated its corporate presentation used for healthcare conferences and investor/analyst outreach; that presentation is attached as Exhibit 99.2.

Key Details

• Filed: Form 8-K dated February 24, 2026 reporting results for Q4 and FY ended December 31, 2025.
• Press release: Furnished as Exhibit 99.1 (financial results and recent developments).
• Presentation: Updated corporate presentation attached as Exhibit 99.2 and intended for use with analysts, stockholders and conference audiences.
• Technical filing note: Cover Page Interactive Data included (Inline XBRL — Exhibit 104).
• The 8-K does not report any leadership changes, mergers, bankruptcies or other corporate actions beyond the financial release and presentation update.

Why It Matters

• This 8-K is the company’s official disclosure of its most recent quarterly and full-year financial performance; investors should review the Exhibit 99.1 press release for revenue, earnings, cash position, guidance and any business updates or clinical/program milestones disclosed. The updated Exhibit 99.2 presentation may provide refreshed messaging on strategy, pipeline progress, upcoming catalysts and investor priorities. Together, these materials contain the facts investors need to assess near-term financial results and company direction.